Skip to main content
SpringerLink
Log in

Summary and Future Directions of ADCs

  • Chapter
  • First Online:
Antibody-Drug Conjugates

Part of the book series: AAPS Advances in the Pharmaceutical Sciences Series ((AAPS,volume 17))

  • 3119 Accesses

Abstract

Antibody-drug conjugates (ADCs) have recently become an important class of oncology therapeutics, offering potent antitumor activity along with reduced side effects to the patients. Although there are only two Food and Drug Administration (FDA)-approved ADCs, the field has the potential for rapid growth with more than 40 candidates in clinical trials. In this chapter, a detailed overview of ADCs currently in the clinics is presented. The main challenges, as well as new technologies and approaches in improving ADCs, are also discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Aird RE, Thomson M, Macpherson JS, Thurston DE, Jodrell DI, Guichard SM (2008) ABCB1 genetic polymorphism influences the pharmacology of the new pyrrolobenzodiazepine derivative SJG –136. Pharmacogenomics J 8(4):289–296

    Article  CAS  PubMed  Google Scholar 

  • Behrens CR, Liu B (2014) Methods for site-specific drug conjugation to antibodies. mAbs 6(1):46–53

    Article  PubMed Central  PubMed  Google Scholar 

  • Bernardes GJ, Casi G, Trussel S, Hartmann I, Schwager K, Scheuermann J, Neri D (2012) A traceless vascular-targeting antibody-drug conjugate for cancer therapy. Angew Chem 51(4):941–944

    Article  CAS  Google Scholar 

  • Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L, Roy S, Sridhara R, Rahman A, Williams G, Pazdur R (2001) Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clinical cancer research: an official journal of the American Association for Cancer Res 7(6):1490–1496

    CAS  Google Scholar 

  • Carter PJ, Senter PD (2008) Antibody-drug conjugates for cancer therapy. Cancer J 14(3):154–169

    Article  CAS  PubMed  Google Scholar 

  • Chari RV (2008) Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res 41(1):98–107

    Article  CAS  PubMed  Google Scholar 

  • Dinndorf PA, Andrews RG, Benjamin D, Ridgway D, Wolff L, Bernstein ID (1986) Expression of normal myeloid-associated antigens by acute leukemia cells. Blood 67(4):1048–1053

    CAS  PubMed  Google Scholar 

  • Dornan D, Bennett F, Chen Y, Dennis M, Eaton D, Elkins K, French D, Go MA, Jack A, Junutula JR, Koeppen H, Lau J, McBride J, Rawstron A, Shi X, Yu N, Yu SF, Yue P, Zheng B, Ebens A, Polson AG (2009) Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood 114(13):2721–2729

    Article  CAS  PubMed  Google Scholar 

  • Dubowchik GM, Firestone RA (1998) Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin. Bioorg Med Chem Lett 8(23):3341–3346

    Article  CAS  PubMed  Google Scholar 

  • Falini B, Pileri S, Pizzolo G, Durkop H, Flenghi L, Stirpe F, Martelli MF, Stein H (1995) CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood 85(1):1–14

    CAS  PubMed  Google Scholar 

  • Guichard SM, Macpherson JS, Thurston DE, Jodrell DI (2005) Influence of P-glycoprotein expression on in vitro cytotoxicity and in vivo antitumour activity of the novel pyrrolobenzodiazepine dimer SJG-136. Eur J cancer 41(12):1811–1818

    Article  CAS  PubMed  Google Scholar 

  • Hamblett KJ, Senter PD, Chace DF, Sun MM, Lenox J, Cerveny CG, Kissler KM, Bernhardt SX, Kopcha AK, Zabinski RF, Meyer DL, Francisco JA (2004) Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res 10(20):7063–7070

    Article  CAS  PubMed  Google Scholar 

  • Hartley JA, Hochhauser D (2012) Small molecule drugs—optimizing DNA damaging agent-based therapeutics. Curr Opin Pharmacol 12(4):398–402

    Article  CAS  PubMed  Google Scholar 

  • Horoszewicz JS, Kawinski E, Murphy GP (1987) Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 7(5B):927–935

    CAS  PubMed  Google Scholar 

  • Israeli RS, Powell CT, Fair WR, Heston WD (1993) Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res 53(2):227–230

    CAS  PubMed  Google Scholar 

  • Janeway C, Travers P, Walport M, Shlomchik M (2001) Immunobiology. The immune system in health and disease. Garland Science, New York

    Google Scholar 

  • Junttila TT, Li G, Parsons K, Phillips GL, Sliwkowski MX (2011) Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Tr 128(2):347–356

    Article  CAS  Google Scholar 

  • Junutula JR, Raab H, Clark S, Bhakta S, Leipold DD, Weir S, Chen Y, Simpson M, Tsai SP, Dennis MS, Lu Y, Meng YG, Ng C, Yang J, Lee CC, Duenas E, Gorrell J, Katta V, Kim A, McDorman K, Flagella K, Venook R, Ross S, Spencer SD, Lee Wong W, Lowman HB, Vandlen R, Sliwkowski MX, Scheller RH, Polakis P, Mallet W (2008) Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol 26(8):925–932

    Article  CAS  PubMed  Google Scholar 

  • Kovtun YV, Audette CA, Mayo MF, Jones GE, Doherty H, Maloney EK, Erickson HK, Sun X, Wilhelm S, Ab O, Lai KC, Widdison WC, Kellogg B, Johnson H, Pinkas J, Lutz RJ, Singh R, Goldmacher VS, Chari RV (2010) Antibody-maytansinoid conjugates designed to bypass multidrug resistance. Cancer Res 70(6):2528–2537

    Article  CAS  PubMed  Google Scholar 

  • Linenberger ML (2005) CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance. Leukemia 19(2):176–182

    Article  CAS  PubMed  Google Scholar 

  • LoRusso PM, Weiss D, Guardino E, Girish S, Sliwkowski MX (2011) Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clin Cancer Res 17(20):6437–6447

    Article  CAS  PubMed  Google Scholar 

  • Lyon RP, Meyer DL, Setter JR, Senter PD (2012) Conjugation of anticancer drugs through endogenous monoclonal antibody cysteine residues. Meth Enzymol 502:123–138

    Article  CAS  PubMed  Google Scholar 

  • Magdalan J, Ostrowska A, Piotrowska A, Izykowska I, Nowak M, Gomulkiewicz A, Podhorska-Okolow M, Szelag A, Dziegiel P (2010) alpha-Amanitin induced apoptosis in primary cultured dog hepatocytes. Folia Histochem Cytobiol 48(1):58–62

    Article  PubMed  Google Scholar 

  • Oflazoglu E, Stone IJ, Gordon KA, Grewal IS, van Rooijen N, Law CL, Gerber HP (2007) Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN –30. Blood 110(13):4370–4372

    Article  CAS  PubMed  Google Scholar 

  • Palumbo A, Hauler F, Dziunycz P, Schwager K, Soltermann A, Pretto F, Alonso C, Hofbauer GF, Boyle RW, Neri D (2011) A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels. Br J Cancer 104(7):1106–1115

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Peiper SC, Ashmun RA, Look AT (1988) Molecular cloning, expression, and chromosomal localization of a human gene encoding the CD33 myeloid differentiation antigen. Blood 72(1):314–321

    CAS  PubMed  Google Scholar 

  • Perrino E, Steiner M, Krall N, Bernardes GJ, Pretto F, Casi G, Neri D (2014) Curative properties of noninternalizing antibody-drug conjugates based on maytansinoids. Cancer Res 74(9):2569–2578

    Article  CAS  PubMed  Google Scholar 

  • Pietersz GA, Rowland A, Smyth MJ, McKenzie IF (1994) Chemoimmunoconjugates for the treatment of cancer. Adv Immunol 56:301–387

    Article  CAS  PubMed  Google Scholar 

  • Press MF, Cordon-Cardo C, Slamon DJ (1990) Expression of the HER –2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 5(7):953–962

    CAS  PubMed  Google Scholar 

  • Sapra P, Hooper AT, O’Donnell CJ, Gerber HP (2011) Investigational antibody drug conjugates for solid tumors. Expert Opin Investig Drugs 20(8):1131–1149

    Article  CAS  PubMed  Google Scholar 

  • Senter PD, Sievers EL (2012) The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol 30 (7):631–637

    Article  CAS  PubMed  Google Scholar 

  • Shen BQ, Xu K, Liu L, Raab H, Bhakta S, Kenrick M, Parsons-Reponte KL, Tien J, Yu SF, Mai E, Li D, Tibbitts J, Baudys J, Saad OM, Scales SJ, McDonald PJ, Hass PE, Eigenbrot C, Nguyen T, Solis WA, Fuji RN, Flagella KM, Patel D, Spencer SD, Khawli LA, Ebens A, Wong WL, Vandlen R, Kaur S, Sliwkowski MX, Scheller RH, Polakis P, Junutula JR (2012) Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol 30(2):184–189

    Article  CAS  PubMed  Google Scholar 

  • Smellie M, Bose DS, Thompson AS, Jenkins TC, Hartley JA, Thurston DE (2003) Sequence-selective recognition of duplex DNA through covalent interstrand cross-linking: kinetic and molecular modeling studies with pyrrolobenzodiazepine dimers. Biochemistry 42(27):8232–8239

    Article  CAS  PubMed  Google Scholar 

  • Teicher BA, Chari RV (2011) Antibody conjugate therapeutics: challenges and potential. Clin Cancer Res 17(20):6389–6397

    Article  CAS  PubMed  Google Scholar 

  • Thayer A (2014) Building Antibody-Drug Conjugates. Chem Eng News 92(3):13–21

    Google Scholar 

  • Tolcher AW, Sugarman S, Gelmon KA, Cohen R, Saleh M, Isaacs C, Young L, Healey D, Onetto N, Slichenmyer W (1999) Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. J Clin Oncol 17(2):478–484

    CAS  PubMed  Google Scholar 

  • Walter RB, Raden BW, Hong TC, Flowers DA, Bernstein ID, Linenberger ML (2003) Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells. Blood 102(4):1466–1473

    Article  CAS  PubMed  Google Scholar 

  • Wang L, Amphlett G, Blattler WA, Lambert JM, Zhang W (2005) Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry. Protein Sci 14(9):2436–2446

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Wang X, Ma D, Olson WC, Heston WD (2011) In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatin-conjugated antibody to prostate-specific membrane antigen. Mol Cancer Ther 10(9):1728–1739

    Article  CAS  PubMed  Google Scholar 

  • Wu AM, Senter PD (2005) Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol 23(9):1137–1146

    Article  CAS  PubMed  Google Scholar 

  • Zimmerman ES, Heibeck TH, Gill A, Li X, Murray CJ, Madlansacay MR, Tran C, Uter NT, Yin G, Rivers PJ, Yam AY, Wang WD, Steiner AR, Bajad SU, Penta K, Yang W, Hallam TJ, Thanos CD, Sato AK (2014) Production of site-specific antibody-drug conjugates using optimized non-natural amino acids in a cell-free expression system. Bioconjugate Chem 25(2):351–361

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacology and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA, USA

    Jennica L. Zaro & Wei-Chiang Shen

  2. Department of Pharmaceutical Sciences, Western University of Health Sciences, Pomona, CA, USA

    Jeffery Wang

Authors
  1. Jennica L. Zaro
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jeffery Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wei-Chiang Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jennica L. Zaro .

Editor information

Editors and Affiliations

  1. Western University of Health Sciences, Department of Pharmaceutical Sciences, Pomona, California, USA

    Jeffrey Wang

  2. University of Southern California, Department of Pharmacology and Pharmaceutical Sciences, Los Angeles, California, USA

    Wei-Chiang Shen

  3. University of Southern California, Department of Pharmacology and Pharmaceutical Sciences, Los Angeles, California, USA

    Jennica L. Zaro

Rights and permissions

Reprints and permissions

Copyright information

© 2015 American Association of Pharmaceutical Scientists

About this chapter

Cite this chapter

Zaro, J., Wang, J., Shen, WC. (2015). Summary and Future Directions of ADCs. In: Wang, J., Shen, WC., Zaro, J. (eds) Antibody-Drug Conjugates. AAPS Advances in the Pharmaceutical Sciences Series, vol 17. Springer, Cham. https://doi.org/10.1007/978-3-319-13081-1_14

Download citation

Publish with us

Policies and ethics

Search

Navigation